Vancomycin Modified to Combat Growing Antibiotic Resistance Threat

Chemists discover a way to structurally modify vancomycin to make the antibiotic more potent

FDA Grants 510(k) Approval to OraSure and Roche for Drug-of-Abuse Assays

Assays for PCP, cocaine, opiates, and methamphetamine are due on the market later this year.

Surprising Sameness among E. coli Strains Raises Hopes for Global Vaccine

Global comparison of genomic contents reveals close relation between E. coli strains that cause traveler's diarrhea.

Vertex Cystic Fibrosis Combinations Score Clinical Successes

Company says three triple-combination regimens of its CF next-generation correctors succeed in Phase I and Phase II trials, potentially expanding the universe of CF patients who could benefit from treatment

Insys Recommits to “High Ethical Standards” After Five Doctors Indicted on...

U.S. Attorney’s Office for the Southern District of New York and FBI allege that the doctors accepted fees for sham educational programs in exchange for prescribing millions of dollars’ worth of Subsys®

4SC Discovery Partners with Heidelberg, Wins $1.79M toward New Malaria Drug

4SC Discovery is teaming up with Heidelberg University Hospital and also receiving a $1.79M grant toward development of an ingredient that can target strains of malaria resistant to conventional drugs.

Ambrx and Wyeth Sign Multitarget Alliance to Develop Protein Drugs

Deal will exploit Ambrx’ biologics optimization technologies, ReCODE™ and EuCODE™. They enable site-selective substitution of novel amino acids.

AstraZeneca Withdraws BLA for Prophylactic Use of mAb in RSV

Firm incurs $455 million charge but will continue developing the antibody for RSV.

Seattle and Millennium Report 75% Response Rate in Pivotal ADC Hodgkin...

Brentuximab vedotin on track for BLA filing with FDA during first half of 2011.

Proteinopathy Cleared Up after Cargo Receptor Made to Give Up Misfolded...

A novel mechanism for the entrapment of misfolded proteins by cargo receptor-containing vesicles suggests a pharmacological strategy for the release of these proteins and their redirection to the lysosome, potentially relieving toxic proteinopathies such as MUC1 kidney disease.

Recently Featured

Stay Connected

Scroll Up